5 registered trials, newest registry update first. Showing only trials linked to Larazotide.
| Trial | Compound | Phase | Status | Sponsor | Enrolled | Primary completion | Registry updated |
|---|---|---|---|---|---|---|---|
| AT1001 for the Treatment of Long COVID NCT05747534 | Larazotide | Phase 2 | Completed | Massachusetts General Hospital | 107 | Jun 18, 2026 | Aug 18, 2026 |
| AT1001 for the Treatment of COVID-19 Related MIS-C NCT05022303 | Larazotide | Phase 2 | Terminated | Massachusetts General Hospital | 12 | May 15, 2024 | Jun 13, 2024 |
| Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms NCT03569007 | Larazotide | Phase 3 | Terminated | 9 Meters Biopharma, Inc. | 307 | Jul 21, 2022 | Jul 26, 2022 |
| Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease NCT00889473 | Larazotide | Phase 2 | Completed | 9 Meters Biopharma, Inc. | 42 | Nov 2009 | Sep 20, 2017 |
| A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease NCT01396213 | Larazotide | Phase 2 | Completed | 9 Meters Biopharma, Inc. | 342 | Aug 20, 2013 | Sep 20, 2017 |
Data: ClinicalTrials.gov, U.S. National Library of Medicine. Registered trials only. This table does not report results or recommend anything.
